Evidence map›Paper›PMID 32790000›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2020

Thrombolytic Agents: Nanocarriers in Controlled Release.

Soodabeh Hassanpour, Han-Jun Kim, Arezoo Saadati, Peyton Tebon, Chengbin Xue, Floor W van den Dolder, Jai Thakor, Behzad Baradaran, Jafar Mosafer, Amir Baghbanzadeh and 12 more

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05978791 (Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05978791 unknown statusnot on this mapstarted 2023, after this paper: background citation

Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus

TypeobservationalSponsorThe First Affiliated Hospital with Nanjing Medical UniversityRan2023 to 2024Enrolled24ConditionsArterial ThrombosisArmscollection of venous blood or arterial blood
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Liposomal formulation ofRSC advances · 2025
    Article
  4. Engineered Probiotic-Powered Micro-Rod Robot Bomb for Thrombus-Penetrating Explosion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  5. Review
  6. Rapid Blood Clot Removal via Remote Delamination and Magnetization of Clot Debris.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  7. Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 5 countries.

Soodabeh HassanpourDepartment of Analytical Chemistry, Faculty of Science, Palacky University Olomouc, 17. Listopadu 12, Olomouc, 77146, Czech Republic.
Han-Jun KimDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0001-9238-7238
Arezoo SaadatiPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.
Peyton TebonDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Chengbin XueDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Floor W van den DolderDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Jai ThakorDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.
Jafar MosaferResearch Center of Advanced Technologies in Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, 9519633787, Iran.
Amir BaghbanzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.
Natan Roberto de BarrosDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Mahmoud HashemzaeiDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Zabol University of Medical Sciences, Zabol, 9861618335, Iran.
Kang Ju LeeDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Junmin LeeDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Shiming ZhangDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Wujin SunDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Hyun-Jong ChoDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Samad AhadianDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Nureddin AshammakhiDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Mehmet R DokmeciDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Ahad MokhtarzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.
Ali KhademhosseiniDepartment of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0001-6322-8852
California NanoSystems Institute · USTabriz University of Medical Sciences · IRPalacký University Olomouc · CZTorbat Heydarieh University of Medical Sciences · IRZabol University of Medical Sciences · IR

Funding

Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Treatment of arterial aneurysms using an injectable biomaterialR01HL140951 · NHLBI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2018 to 2021
$2.6M
NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01 HL140951
6 · The paper itself

Abstract

Thrombosis is a life-threatening pathological condition in which blood clots form in blood vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes that can catalyze the conversion of plasminogen to plasmin to dissolve blood clots. The plasmin formed by TAs breaks down fibrin clots into soluble fibrin that finally dissolves thrombi. Several TAs have been developed to treat various thromboembolic diseases, such as pulmonary embolisms, acute myocardial infarction, deep vein thrombosis, and extensive coronary emboli. However, systemic TA administration can trigger non-specific activation that can increase the incidence of bleeding. Moreover, protein-based TAs are rapidly inactivated upon injection resulting in the need for large doses. To overcome these limitations, various types of nanocarriers have been introduced that enhance the pharmacokinetic effects by protecting the TA from the biological environment and targeting the release into coagulation. The nanocarriers show increasing half-life, reducing side effects, and improving overall TA efficacy. In this work, the recent advances in various types of TAs and nanocarriers are thoroughly reviewed. Various types of nanocarriers, including lipid-based, polymer-based, and metal-based nanoparticles are described, for the targeted delivery of TAs. This work also provides insights into issues related to the future of TA development and successful clinical translation.

Indexed as

Myocardial InfarctionThrombosisBlood CoagulationDelayed-Action PreparationsFibrinolytic AgentsHumansDelayed-Action PreparationsFibrinolytic Agentsdrug deliverynanoparticlesplasminogen activatorsthrombolytic agentsthrombosis

Identifiers

PMID32790000
PMCPMC7702193
OpenAlexW3048647521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.